Announcements Trials
Browse Landscape

Phase

Phase 4 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1Lymphoid 1Genitourinary 1

Conditions

Lymphoma, Non-Hodgkin 1Cardiomyopathies 1

Interventions

Rituximab 1371Cyclophosphamide 1296Vincristine 662Doxorubicin 583Etoposide 525Prednisone 504Cytarabine 481fludarabine 461Methotrexate 441Dexamethasone 411fludarabine phosphate 396Lenalidomide 347Filgrastim 342Bendamustine Hydrochloride 274Radiotherapy 266venetoclax 254ibrutinib 249Peripheral Blood Stem Cell Transplantation 233Melphalan 229obinutuzumab 227Granulocyte Colony-Stimulating Factor 212Bortezomib 204Gemcitabine 201Busulfan 186Whole-Body Irradiation 185Mycophenolic Acid 174Tacrolimus 164Specimen Handling 161Calcium Dobesilate 150Magnetic Resonance Spectroscopy 149

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Valsartan × Lymphoid × Clear all
NCT00162955 2012-05-08

Prevention of CHOP-induced Chronic Cardiotoxicity

Osaka City University

Phase 4 Completed
150 enrolled
Lymphoid

Lymphoma, Non-Hodgkin, Cardiomyopathies

Data powered by HemOnc (CC BY 4.0) Colophon âš¡